Edwards Lifesciences Co. (NYSE:EW) Shares Sold by NS Partners Ltd

NS Partners Ltd trimmed its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 1.6% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 205,200 shares of the medical research company’s stock after selling 3,441 shares during the period. NS Partners Ltd’s holdings in Edwards Lifesciences were worth $15,191,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in EW. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Edwards Lifesciences during the 4th quarter worth $30,000. FSA Wealth Management LLC purchased a new position in Edwards Lifesciences in the 3rd quarter valued at about $30,000. Prospera Private Wealth LLC purchased a new position in Edwards Lifesciences in the 3rd quarter valued at about $32,000. Avior Wealth Management LLC raised its stake in shares of Edwards Lifesciences by 138.7% in the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 308 shares in the last quarter. Finally, Roble Belko & Company Inc acquired a new stake in shares of Edwards Lifesciences in the 4th quarter valued at about $46,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Trading Down 2.0 %

Edwards Lifesciences stock opened at $70.36 on Friday. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The firm has a market capitalization of $41.50 billion, a price-to-earnings ratio of 10.10, a P/E/G ratio of 4.82 and a beta of 1.10. The company has a 50 day moving average price of $72.26 and a 200 day moving average price of $70.38.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Research analysts forecast that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other news, Director Steven R. Loranger sold 5,739 shares of the business’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $76.42, for a total transaction of $438,574.38. Following the transaction, the director now directly owns 60,372 shares in the company, valued at $4,613,628.24. The trade was a 8.68 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $75.76, for a total value of $852,300.00. Following the sale, the chief financial officer now directly owns 30,561 shares of the company’s stock, valued at approximately $2,315,301.36. The trade was a 26.91 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 37,739 shares of company stock valued at $2,799,104 in the last 90 days. 1.29% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Citigroup upped their target price on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Piper Sandler increased their price objective on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 12th. Stifel Nicolaus upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and increased their price objective for the stock from $75.00 to $90.00 in a research note on Thursday, January 30th. Canaccord Genuity Group increased their price objective on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a research note on Thursday, February 13th. Finally, Truist Financial reiterated a “hold” rating and set a $78.00 price objective (up previously from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $79.95.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.